Literature DB >> 28993105

Dual trigger of final oocyte maturation in poor ovarian responders undergoing IVF/ICSI cycles.

Jie Zhang1, Yun Wang1, Xiaoyan Mao1, Qiuju Chen1, Qingqing Hong1, Renfei Cai1, Shaozhen Zhang1, Yanping Kuang2.   

Abstract

Previous studies show that a dual trigger ovulation regimen significantly improves number and maturity of retrieved oocytes for normal ovarian responders or patients with history of low oocyte yield. The current retrospective cohort study investigated whether dual trigger of final oocyte maturation may benefit IVF outcomes for poor ovarian responders fulfilling the Bologna criteria. Undertaken between May 2014 and August 2016, the study involved 1350 patients undergoing 1389 IVF/intracytoplasmic sperm injection treatment cycles. Patients triggered with 5000 IU human chorionic gonadotrophin (HCG) alone (328 cycles) were compared with those undergoing dual triggering with 5000 IU HCG plus 0.1 mg gonadotrophin-releasing hormone agonist (GnRHa) (386 cycles) and patients triggered with 10,000 IU HCG (363 cycles) were compared with those undergoing dual triggering with 10,000 IU HCG plus 0.1 mg GnRHa (312 cycles). The dual trigger groups showed significantly higher number of oocytes collected and number of mature oocytes compared with their respective HCG trigger group (P < 0.001). Oocyte retrieval rate and percentage of mature oocytes retrieved were also both significantly higher in the dual trigger groups (P < 0.001). Fertilization rate, number of viable embryos, implantation rate, clinical pregnancy rate and miscarriage rate were not significantly different between groups.
Copyright © 2017 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Dual trigger; Gonadotrophin-releasing hormone agonist; Human chorionic gonadotrophin; IVF; Poor ovarian responders

Mesh:

Substances:

Year:  2017        PMID: 28993105     DOI: 10.1016/j.rbmo.2017.09.002

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  6 in total

Review 1.  Prediction, assessment, and management of suboptimal GnRH agonist trigger: a systematic review.

Authors:  Hadas Ganer Herman; Eran Horowitz; Yossi Mizrachi; Jacob Farhi; Arieh Raziel; Ariel Weissman
Journal:  J Assist Reprod Genet       Date:  2022-03-19       Impact factor: 3.412

2.  Dual Trigger Compared with Human Chorionic Gonadotropin Alone and Effects on Clinical Outcome of Intracytoplasmic Sperm Injection.

Authors:  Bahar Shakerian; Engin Turkgeldi; Sebile Guler Cekic; Sule Yildiz; Ipek Keles; Baris Ata
Journal:  Int J Fertil Steril       Date:  2021-10-16

3.  Dual trigger with gonadotropin-releasing hormone agonist and recombinant human chorionic gonadotropin improves the outcome of intrauterine insemination.

Authors:  Binarwan Halim; Hilma Putri Lubis
Journal:  Obstet Gynecol Sci       Date:  2022-02-21

4.  Clinical efficacy of dual trigger with human chorionic gonadotropin and a gonadotropin-releasing hormone agonist for women undergoing fertility preservation.

Authors:  Yeon Hee Hong; Seul Ki Kim; Jung Ryeol Lee; Byung Chul Jee; Chang Suk Suh
Journal:  Reprod Med Biol       Date:  2022-02-04

5.  Dual trigger improves response to ovarian stimulation and ICSI outcomes in patients with a previous r-hCG triggered ICSI cycle.

Authors:  Amanda Souza Setti; Luis Guilherme Louzada Maldonado; Daniela Paes de Almeida Ferreira Braga; Assumpto Iaconelli; Edson Borges
Journal:  JBRA Assist Reprod       Date:  2022-04-17

6.  Reproductive outcomes of dual trigger with combination GnRH agonist and hCG versus trigger with hCG alone in women undergoing IVF/ICSI cycles: a retrospective cohort study with propensity score matching.

Authors:  Li Dong; Fang Lian; Haicui Wu; Shan Xiang; Yuan Li; Chaofeng Wei; Xiaona Yu; Xin Xin
Journal:  BMC Pregnancy Childbirth       Date:  2022-07-22       Impact factor: 3.105

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.